Mechanotyping of Organoids for Assessing Drug‐Induced Injuries

Abstract

Abstract Changes in the mechanical properties, i.e., mechanotypes, of tissues are powerful indicators of disease states and drug‐induced injuries. Although differential mechanotyping has emerged as a valuable tool for non‐invasive disease diagnostics, it remains particularly underutilized for drug safety and efficacy screening in preclinical studies. This is largely due to the lack of scalable mechanotyping methods compatible with modern 3D organoid models. Here, the Centrifugal Mechanical Testing (CeMeT) platform is presented, which enables rapid, robust, and label‐free mechanotyping of 3D organoids. Utilizing centrifugal mechanical principles and high‐speed imaging, this platform achieves high accuracy and precision and can assess a wide range of tissue stiffness. It is demonstrated that the CeMeT platform distinguishes mechanical properties, i.e., stiffness and elastic recovery, among various hydrogel bead formulations and hiPSC‐derived cardiac organoids, successfully detecting pathological changes in mechanotype with high sensitivity. Through experiments on organoids treated with drugs like pergolide and Cytochalasin‐D, it is established that changes in organoid mechanotypes can serve as reliable indicators of drug‐induced tissue injuries in vitro. These findings position the CeMeT platform as a potentially transformative tool for early‐stage drug safety assessment through mechanotyping, with immediate applications extending to fundamental disease pathology research and drug efficacy testing using organoid models.